Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Outlook 2025 – Insights for Executive and Strategic Planning
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Grown from 2024 to 2025?#_x000D_
The market size of adeno-associated virus (AAV) vectors in gene therapy has witnessed a swift expansion recently, escalating from $2.70 billion in 2024 to $3.18 billion in 2025, representing a compound annual growth rate (CAGR) of 17.7%. This notable growth during the historic period is linked to factors like increased financial input in gene therapy studies, enhanced usage of gene modifying technologies, an upsurge in genetic anomalies and unfulfilled medical necessities, a heightened requirement for specifically targeted therapies, and increased collaborations between biotechnological businesses and research institutions._x000D_
_x000D_
#What Growth Rate Is Anticipated for the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market in the Coming Years?#_x000D_
Anticipated to experience rapid expansion in the near future, the adeno-associated virus (AVV) vectors for gene therapy market is forecasted to reach a value of $6.09 billion by 2029, with a compound annual growth rate (CAGR) of 17.6%. This growth during the forecast period can be chalked up to factors such as advancements in AAV capsid engineering, a heightened focus on precision medicine, increased funding for genetic studies and biotech, a surge in clinical trials and approvals for gene therapies, and a growing need for customised treatments. Key trends to watch out for during the forecast period involve the utilisation of artificial intelligence in AAV capsid engineering, the creation of hybrid AAV vectors that can accommodate larger genetic payloads, innovative practices in bispecific antibody-mediated AAV targeting, enhanced scalable AAV production and purification methods, and the emergence of adaptable AAV platforms that can accommodate a range of viral vectors._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp_x000D_
_x000D_
#Who Are the Leading Companies in the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?#_x000D_
Major companies operating in the adeno-associated virus (AVV) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc._x000D_
_x000D_
#What Are the Key Drivers of the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?#_x000D_
The surge in emphasis on gene-based therapies is anticipated to catalyze the expansion of the adeno-associated virus (AAV) vectors in the gene therapy market. These therapies attempt to amend or control genes to hinder, remediate, or eliminate diseases on a molecular scale. Progress in genetic research insights the intensified priority on establishing gene-based therapies that elevate the precision and efficacy of gene editing methods. The use of adeno-associated virus (AAV) vectors in gene therapy contributes to the formation of gene therapies by safely and effectively delivering therapeutic genes into the necessary cells, credited to their minimal immunogenicity and competency to offer sustained gene expression. For example, IQVIA, an American firm offering advanced analytical and technology solutions for the life sciences sector, reported a global expenditure of $5.9 billion on cell and gene therapies in 2023, marking a 38% rise from 2022. Therefore, the escalating emphasis on developing gene-based therapies propels the expansion of the adeno-associated virus (AAV) vectors market._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp_x000D_
_x000D_
#What Are the Key Market Segments in the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Industry?#_x000D_
The adeno-associated virus (AVV) vectors in gene therapy market covered in this report is segmented –_x000D_
_x000D_
1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy_x000D_
2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo_x000D_
3) By Scale of Operation: Preclinical, Clinical, Commercial_x000D_
4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area_x000D_
_x000D_
Subsegments:_x000D_
1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders_x000D_
2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering_x000D_
3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine_x000D_
_x000D_
#What Are the Latest Trends in the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?#_x000D_
Leading firms in the adeno-associated virus (AAV) vectors within the gene therapy sector are prioritizing sophisticated innovations, such as bespoke vector diversity for assay versatility. This can enhance tissue specificity, boost therapeutic efficiency, and expedite the creation of tailored gene therapies for various conditions. Bespoke vector diversity for assay versatility implies the utilization of multiple AAV serotypes or constructs to accommodate different analytical tests and therapeutic functions. For example, in May 2024, US-based pharmaceutical entity Charles River Laboratories launched new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV). This initiative aims to meet the expanding requirements of cell and gene therapy (CGT) development. The collection simplifies the transition from preliminary research to GMP-grade manufacturing. It contributes to standardization and enhances reliability in viral vector production. This introduction tackles a significant obstacle in elevating CGT programmes towards clinical and commercial preparedness._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#What Are the Key Regional Markets in the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Industry?#_x000D_
North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2024. The regions covered in the adeno-associated virus (AVV) vectors in gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=24135&type=smp_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the adeno-associated virus (avv) vectors in gene therapy market, and how is it changing globally?_x000D_
2. Who are the major companies in the adeno-associated virus (avv) vectors in gene therapy market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the adeno-associated virus (avv) vectors in gene therapy market right now?_x000D_
4. Which products or customer segments are growing the most in the adeno-associated virus (avv) vectors in gene therapy market?_x000D_
5. What factors are helping or slowing down the growth of the adeno-associated virus (avv) vectors in gene therapy market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Europe +44 7882 955267_x000D_
Asia & Others +44 7882 955267 & +91 8897263534_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
